253 related articles for article (PubMed ID: 12698302)
21. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
Rosenkranz B
Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
[TBL] [Abstract][Full Text] [Related]
22. Hypoglycemia in hospitalized patients treated with sulfonylureas.
Deusenberry CM; Coley KC; Korytkowski MT; Donihi AC
Pharmacotherapy; 2012 Jul; 32(7):613-7. PubMed ID: 22570146
[TBL] [Abstract][Full Text] [Related]
23. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
24. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.
Holstein A; Plaschke A; Ptak M; Egberts EH; El-Din J; Brockmöller J; Kirchheiner J
Br J Clin Pharmacol; 2005 Jul; 60(1):103-6. PubMed ID: 15963101
[TBL] [Abstract][Full Text] [Related]
25. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
26. [Incidence of severe hypoglycemia in relation to metabolic control and patient knowledge].
Ratzmann KP; Schimke E
Med Klin (Munich); 1995 Oct; 90(10):557-61. PubMed ID: 7500918
[TBL] [Abstract][Full Text] [Related]
27. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study.
Martin S; Kolb H; Beuth J; van Leendert R; Schneider B; Scherbaum WA
Diabetologia; 2003 Dec; 46(12):1611-7. PubMed ID: 14600814
[TBL] [Abstract][Full Text] [Related]
28. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas.
Sato R; Watanabe H; Genma R; Takeuchi M; Maekawa M; Nakamura H
Pharmacogenomics; 2010 Dec; 11(12):1743-50. PubMed ID: 21142918
[TBL] [Abstract][Full Text] [Related]
29. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide.
Klepzig H; Kober G; Matter C; Luus H; Schneider H; Boedeker KH; Kiowski W; Amann FW; Gruber D; Harris S; Burger W
Eur Heart J; 1999 Mar; 20(6):439-46. PubMed ID: 10213347
[TBL] [Abstract][Full Text] [Related]
30. Effects of glimepiride and glibenclamide on carotid atherosclerosis in type 2 diabetic patients.
Katakami N; Kaneto H; Matsuhisa M; Shimomura I; Yamasaki Y
Diabetes Res Clin Pract; 2011 Apr; 92(1):e20-2. PubMed ID: 21257219
[TBL] [Abstract][Full Text] [Related]
31. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
Sonnenberg GE; Garg DC; Weidler DJ; Dixon RM; Jaber LA; Bowen AJ; DeChemey GS; Mullican WS; Stonesifer LD
Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
[TBL] [Abstract][Full Text] [Related]
32. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia.
Holstein A; Hahn M; Patzer O; Seeringer A; Kovacs P; Stingl J
Eur J Clin Pharmacol; 2011 May; 67(5):471-6. PubMed ID: 21213107
[TBL] [Abstract][Full Text] [Related]
33. [Glimepiride--an oral antidiabetic agent].
Becić F; Kapić E; Becić E
Med Arh; 2003; 57(2):125-7. PubMed ID: 12822388
[TBL] [Abstract][Full Text] [Related]
34. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.
van Dalem J; Brouwers MC; Stehouwer CD; Krings A; Leufkens HG; Driessen JH; de Vries F; Burden AM
BMJ; 2016 Jul; 354():i3625. PubMed ID: 27413017
[TBL] [Abstract][Full Text] [Related]
35. Long-acting sulfonylureas -- long-acting hypoglycaemia.
Veitch PC; Clifton-Bligh RJ
Med J Aust; 2004 Jan; 180(2):84-5. PubMed ID: 14723592
[No Abstract] [Full Text] [Related]
36. Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older.
Greco D; Pisciotta M; Gambina F; Maggio F
Exp Clin Endocrinol Diabetes; 2010 Apr; 118(4):215-9. PubMed ID: 20072965
[TBL] [Abstract][Full Text] [Related]
37. Glibenclamide induced prolonged hypoglycaemia.
Sonnenblick M; Shilo S
Age Ageing; 1986 May; 15(3):185-9. PubMed ID: 3090865
[TBL] [Abstract][Full Text] [Related]
38. The differential influence of glimepiride and glibenclamide on insulin resistance and adiponectin levels in patients with type 2 diabetes.
Emini-Sadiku M; Car N; Begolli L; Blaslov K; Haliti E; Bahtiri E
Endocr J; 2019 Oct; 66(10):915-921. PubMed ID: 31292311
[TBL] [Abstract][Full Text] [Related]
39. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
Vexiau P; Mavros P; Krishnarajah G; Lyu R; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():16-24. PubMed ID: 18435670
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
Hermansen K; Kolotkin RL; Hammer M; Zdravkovic M; Matthews D
Prim Care Diabetes; 2010 Jul; 4(2):113-7. PubMed ID: 20444662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
